Graviton Biosciences

Graviton Biosciences is a clinical-stage biotechnology company dedicated to developing next-generation therapeutics for autoimmune, inflammatory, and fibrotic diseases. The company's core expertise lies in the development of highly selective inhibitors of Rho-associated coiled-coil containing protein kinase 2 (ROCK2), a key regulator of immune and fibrotic pathways. Its lead candidate, GV-101, is currently being evaluated in Phase 2 clinical trials for indications including idiopathic pulmonary fibrosis and Dupuytren's contracture. Beyond its lead program, Graviton is advancing a pipeline of ROCK2 inhibitors designed to penetrate the blood-brain barrier for the treatment of central nervous system disorders. The company was founded by Dr. Samuel Waksal, a seasoned biotech entrepreneur known for founding ImClone Systems and Kadmon Holdings. Graviton aims to leverage its deep understanding of ROCK2 biology to provide transformative treatments for patients with high unmet medical needs.